YERVOY

NEUROLOGIC

Immune-related neuropathies1

neurologic

  • YERVOY™ is associated with serious immune-related neurological adverse reactions. Fatal Guillain-Barré syndrome and myasthenia gravis-like symptoms have been reported in clinical trials
  • Patients should be advised to immediately report signs or symptoms, such as muscle weakness or sensory neuropathy
  • Monitor patients for signs or symptoms of motor and sensory neuropathy
  • Withhold YERVOY™ in patients with moderate neuropathy (motor with or without sensory)
  • Permanently discontinue YERVOY™ in patients with:
    - New onset or worsening of severe motor or sensory neuropathy, Guillain-Barré syndrome, or myasthenia gravis
    - Severe motor neuropathy, regardless of causality
  • Systemic high-dose corticosteroid therapy may be required

neurologic

neurologic

Back to Overview

Next (ENDOCRINE) 

1. YERVOY™ Summary of Product Characteristics.

Senast uppdaterad:  2015-07-02Ansvarig:  Anna Labecker